NASDAQ:RARX - Ra Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.06 +1.15 (+7.23 %)
(As of 12/12/2018 04:00 PM ET)
Previous Close$15.91
Today's Range$16.6899 - $18.50
52-Week Range$4.78 - $19.80
Volume3.01 million shs
Average Volume278,540 shs
Market Capitalization$533.27 million
P/E Ratio-7.08
Dividend YieldN/A
Beta2.11
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
Previous Symbol
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio10.30
Quick Ratio10.30

Price-To-Earnings

Trailing P/E Ratio-7.08
Forward P/E Ratio-8.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales112.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.06 per share
Price / Book5.58

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-72.35%
Return on Assets-64.78%

Miscellaneous

Employees63
Outstanding Shares32,400,000
Market Cap$533.27 million
OptionableOptionable

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

5 brokerages have issued 1 year price targets for Ra Pharmaceuticals' stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Ra Pharmaceuticals' stock price to reach $32.40 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media headlines about RARX stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 41)
  • Dr. Simon Read, Chief Scientific Officer (Age 47)
  • Mr. Alonso Ricardo, Sr. VP of R&D

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.34%), First Manhattan Co. (3.32%), Vanguard Group Inc. (2.28%), Candriam Luxembourg S.C.A. (1.35%), Dimensional Fund Advisors LP (1.22%) and Citadel Advisors LLC (1.02%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which institutional investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Citadel Advisors LLC and FMR LLC. View Insider Buying and Selling for Ra Pharmaceuticals.

Which institutional investors are buying Ra Pharmaceuticals stock?

RARX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Manhattan Co., Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Point72 Asset Management L.P. and Algert Global LLC. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $17.06.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $533.27 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Net Asset Value (NAV)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel